Cardiovascular Pharmacology: Open Access

Golovach SV

Publications

• Commentry
  Hypertrophic and Inflammatory Markers in Isoproterenol-Induced CardiacHypertrophy and its Pharmacological Correction
  Author(s): Sukoyan GV, Golovach SV, Dolidze NM, Kezeli TD, Gongadze NV, Chipashvili M and Okujava MVSukoyan GV, Golovach SV, Dolidze NM, Kezeli TD, Gongadze NV, Chipashvili M and Okujava MV
  
  Backgrounds: Short-term sustained beta-adrenergic stimulation is a hallmark of sympathetic hyperactivity and a common future in cardiovascular disease. Activation of endogenous cell signaling pathways that negatively regulate cardiac hypertrophy including the decline of NAD and the reduction of the intracellular NAD+/NADH ratio. The hypothesis that prevention of NAD depletion in myocardium may be critical in the treatment of cardiac hypertrophy and inflammatory responses was tested. Methods: On the 7 days of isoproterenol (ISO)-induced cardiac hypertrophy (CH) all animals were randomly assigned into 3 groups: control-without therapy (infusion of 0,9% NaCl); main I-receive 10 mg/kg nebivolol per os in combination with lisinopril infusion; and main II-receive infusion of 15 mg/kg of Nadcin® dissolved in water for injection. All animals were euthanized thro.. View More»
  DOI: 10.4172/2329-6607.1000225

  Abstract PDF